4.6 Article

Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction

Journal

Publisher

WILEY
DOI: 10.1111/eci.13401

Keywords

antidepressants; depression; heart failure; HFpEF outcome

Funding

  1. National Natural Science Foundation of China [81770392, 81770394, 81700344, 81800344, 81800345]
  2. Science and Technology Program Foundation of Guangzhou [201707010124]
  3. Guangdong Natural Science Foundation [2017A030310311, 2017A030313795]
  4. Young Teachers' Basic Scientific Research Business Expenses Project [20ykpy72]
  5. Medical Research Foundation of Guangdong Province [A2017030, A2018107, A2018082]
  6. China Postdoctoral Science Foundation [2019M663312, 2019TQ0380, 2019M660229]

Ask authors/readers for more resources

Limited data on depression in HFpEF patients and the efficacy of antidepressants. Study found no significant association between baseline major depression and cardiovascular outcomes in HFpEF patients. Treatment with antidepressants did not affect prognosis in HFpEF patients with major depression.
Objective Limited data have been published concerning about depression in heart failure with preserved ejection fraction (HFpEF). Besides, among HFpEF patients with depression, the efficacy of antidepressants is poorly defined. Therefore, our current study was aimed to examine the relationship between major depression and clinical outcomes in HFpEF patients and further address the effects of antidepressants on prognosis in patients with major depression and HFpEF. Methods A total of 1431 patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT) were divided into 2 groups according to the baseline depression status. Major depression was diagnosed if the Patient Health Questionnaire-9 score (PHQ-9) >= 10. Univariable and multivariable Cox proportional hazards models tested the association of major depression with outcomes and the effects of antidepressants among HFpEF patients with major depression during a follow-up of 6 years. Results 26.7% (382/1431) of patients were diagnosed with major depression. After multivariable adjustment, major depression at baseline was not significantly associated with cardiovascular outcomes (fully adjusted hazard ratio (aHR) 0.95 [0.76-1.18] for primary outcomes; aHR: 0.86 [0.67-1.10] for HF hospitalization; aHR: 1.06 [0.91-1.23] for any hospitalization; aHR: 1.00 [0.70-1.43] for cardiovascular death; aHR: 1.24 [0.96-1.61] for all-cause death). Additionally, among HFpEF patients with major depression, the use of antidepressants was not associated with adverse events (P > .05 for all analyses). Conclusions In HFpEF patients, major depression at baseline did not increase mortality or rehospitalization. Additionally, treatment with antidepressants might not improve prognosis among HFpEF patients with major depression. Future studies are warranted to explore the effects of antidepressants on HFpEF patients with depression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available